Claims
- 1. A vitamin D analog compound selected from the group consisting of (4E,6E)-7-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl}-3-ethylnona-4,6-dien-3-ol, (E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)phenyl]-1,1,1 -trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, (3E,5E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)-phenyl]1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, (E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)ethyl]-phenyl}-1,1,1-trifluoro-2-trifluorometthyloct-5-en-3-yn-2-ol, and (3E,5E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien- 2-ol, and the geometric isomers thereof and these compounds in which one or more of the hydroxyl functions are protected by a protective group —(C═O)—R, in which R is a linear or branched alkyl radical having from 1 to 6 carbon atoms, an aryl radical having from 6 to 10 carbon atoms, or an aralkyl radical having from 7 to 11 carbon atoms, the aryl radical or the aralkyl radical optionally being mono-or disubstituted by a hydroxy group, an alkoxy radical having from 1 to 3 carbon atoms, a halogen atom, a nitro function or by an amino function, and mixtures thereof.
- 2. The vitamin D analog compound as defined by claim 1, comprising at least are protective group —(C═O)—R, in which R is a methyl, ethyl, isopropyl, tert-butyl or hexyl radical.
- 3. The vitamin D analog compound as defined by claim 1, comprising at least one protective group —(C═O)—R, in which R is a phenyl or naphthyl radical.
- 4. The vitamin D analog compound as defined by claim 1, comprising at least one protective group —(C═O)—R, in which R is a benzyl or methylnaphthyl radical.
- 5. The vitamin D analog compound as defined by claim 1, comprising at least one protective group —(C═O)—R, in which R is a fluorine, bromine or chlorine atom.
- 6. A pharmaceutical composition comprising an effective cell proliferation and differentiation affecting amount of at least one vitamin D analog compound as defined by claim 1, formulated into a pharmaceutically acceptable support therefor.
- 7. The pharmaceutical composition as defined by claim 6, further comprising at least one retinoid, corticosteroid, estrogen, antioxidant, α-hydroxy acid, β-hydroxy acid, α-keto acid or derivative thereof, ion channel blocker, immune system affecting active agent, or mixture thereof.
- 8. The pharmaceutical composition as defined by claim 6, said at least one vitamin D analog compound comprising from 0.0001% to 5% by weight thereof.
- 9. The pharmaceutical composition as defined by claim 6, formulated as tablets, capsules, a syrup, a suspension, a powder, granules, an emulsion, micropheres, nanospheres, controlled release lipid vesicles or polymers, a solution, a salve, a cream, a milk, an ointment, a lotion, a gel, a spray, or a swab.
- 10. A cosmetic composition comprising a skin/hair cosmetically effective amount of at least one vitamin D analog compound as defined by claim 1, formulated into a cosmetically acceptable support therefor.
- 11. The cosmetic composition as defined by claim 10, further comprising at least one retinoid, corticosteroid, antioxidant, α-hydroxy or α-keto acid or derivative thereof, ion channel blocker, or mixture thereof.
- 12. The cosmetic composition as defined by claim 10, said at least one vitamin D analog compound comprising from 0.001% to 3% by weight thereof.
- 13. The cosmetic composition as defined by claim 10, formulated as a cream, a lotion, a gel, microspheres, nanospheres, lipid or polymer vesicles, a soap, or a shampoo.
- 14. A regime or regimen for influencing the transactivation of vitamin D response elements in an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 15. A regime or regimen for treating a dermatological complaint, condition or affliction associated with a keratinization disorder, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 16. A regime or regimen for treating ichthyosis, an ichthyosiform state, Darrier's syndrome, palmoplantar keratodermia, leucoplasia, a leucoplasiform state, or cutaneous or mucous (buccal) lichen, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 17. A regime or regimen for treating a dermatological complaint, condition or affliction having an inflammatory immunoallergic component, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 18. A regime or regimen for treating dermal or epidermal proliferation, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 19. A regime or regimen for treating an immune dermatosis, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 20. A regime or regimen for treating a dermatological or general complaint, condition or affliction having an immunological component on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 21. A regime or regimen for treating a sebaceous function disorder, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 22. A regime or regimen for treating a cutaneous disorder caused by UV radiation, or aging of the skin, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 23. A regime or regimen for treating a cicatrization disorder or stretch marks, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 24. A regime or regimen for treating an inflammatory complaint, condition or affliction, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 25. A regime or regimen for treating an ophthalmological complaint, condition or affliction, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 26. A regime or regimen for treating a cancerous or precancerous state having or being induced by vitamin D receptors, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 27. A regime or regimen for treating alopecia, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 28. A regime or regimen for treating an immune complaint, condition or affliction, on an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 29. A regime or regimen for treating an endocrine complaint, condition or affliction, on or in an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 30. A regime or regimen for treating abnormal management of intracellular calcium, or a calcium metabolism pathology, on or in an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 31. A regime or regimen for treating a vitamin D deficiency, or a disorder of the homeostasis of minerals in the plasma and the bones, on or in an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 32. A regime or regimen for treating a complaint, condition or affliction of the cardiovascular system, in an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
- 33. A regime or regimen for treating non-insulin-dependant diabetes, in an individual in need of such treatment, comprising administering to such individual, a thus effective amount of the pharmaceutical composition as defined by claim 6.
Priority Claims (1)
| Number |
Date |
Country |
Kind |
| 01/06731 |
May 2001 |
FR |
|
CROSS-REFERENCE TO PRIORITY/PCT APPLICATIONS
[0001] This application claims priority under 35 U.S.C. § 119 of FR-01/06731, filed May 22, 2001, and is a continuation of PCT/FR 02/01726, filed May 22, 2002 and designating the United States (published in the French language on Nov. 28, 2002 as WO 02/094754 A1; the title and abstract were also published in English), both hereby expressly incorporated by reference.
Continuations (1)
|
Number |
Date |
Country |
| Parent |
PCT/FR02/01726 |
May 2002 |
US |
| Child |
10718538 |
Nov 2003 |
US |
Patent Application
20040224929
